Latest news with #WINREVAIR
Yahoo
20-07-2025
- Business
- Yahoo
Merck's (MRK) Dividend History: A Track Record of Consistency
Merck & Co., Inc. (NYSE:MRK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A close-up of a person's hand holding a bottle of pharmaceuticals. The company has a strong lineup of products in development and brings in solid revenue and earnings. It remains focused on innovation, with recent regulatory approvals including Winrevair, a treatment for pulmonary arterial hypertension, and Enflonsia, a vaccine targeting respiratory syncytial virus (RSV). Merck & Co., Inc. (NYSE:MRK) reported solid earnings in the first quarter of 2025. The company's revenue came in at $15.5 billion, down nearly 2% from the same period last year, but beat analysts' estimates by over $198 million. Sales of KEYTRUDA rose by 4% to reach $7.2 billion, or 6% growth when adjusted for foreign exchange effects. WINREVAIR brought in $280 million in revenue. Meanwhile, Merck's Animal Health segment saw a 5% increase in sales to $1.6 billion, and a 10% rise when excluding the impact of currency fluctuations. In addition to these quarterly earnings, Merck & Co., Inc. (NYSE:MRK) has shown its resilience as a dividend stock. The company has been rewarding shareholders with growing dividends for the past 14 years. Currently, it offers a quarterly dividend of $0.81 per share and has a dividend yield of 4.05%, as of July 17. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
14-07-2025
- Business
- Yahoo
Merck (NYSE:MRK) To Present Promising HIV Research Data At IAS 2025 In Kigali
Merck recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ongoing project developments and regulatory updates, such as the FDA's acceptance of a supplemental Biologics License Application for WINREVAIR, might have bolstered investor sentiment. Over the last quarter, Merck's share price increased by 2.47%. During this period, broader market movements, including trade uncertainties affecting major indices, showed mixed directions, with the overall market staying relatively flat, suggesting Merck's performance aligned with the broader market trends. Every company has risks, and we've spotted 1 weakness for Merck you should know about. These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch. The recent updates on Merck's HIV research, paired with developments related to the supplemental Biologics License Application for WINREVAIR, hold potential implications for the company's growth narrative. These advancements might positively influence Merck's revenue by bolstering its product pipeline, which is projected to introduce over 20 new growth drivers with significant commercial potential. As a result, long-term earnings forecasts could see an upward adjustment, aligning with the company's efforts to maintain leadership in key therapeutic areas. Over a five-year period, Merck's total return, encompassing both share price appreciation and dividends, was 28.14%. This is noteworthy given the 12.5% return for the US market over the past year, despite the company's underperformance relative to the broader market and industry decline. Such performance over time suggests resilience and long-term growth potential, despite facing short-term market volatility and challenges from competitors within the pharmaceuticals sector. Regarding the current share price, which sits at US$79.04, Merck's price target of US$105.02 implies a potential share price increase of 24.7%. The market's reaction to the company's recent news could be a contributing factor to bridging this gap, if the projected growth in revenue and earnings materializes effectively. Investors might consider these elements in evaluating Merck's long-term value proposition. According our valuation report, there's an indication that Merck's share price might be on the cheaper side. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
06-07-2025
- Business
- Yahoo
FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR
Merck & Co., Inc. (NYSE:MRK) is one of the . On July 2, Merck & Co., Inc. (NYSE:MRK) announced that the FDA has accepted and granted priority review to its supplemental Biologics License Application for WINREVAIR. Merck & Co., Inc.'s (NYSE:MRK) WINREVAIR was previously approved in 2024 for treating adults with pulmonary arterial hypertension. The treatment aims to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. The current application seeks to update the US product label based on the results of the Phase 3 ZENITH trial. A close-up of a person's hand holding a bottle of pharmaceuticals. The ZENITH trial is notable for being the first Phase 3 PAH study to use a primary endpoint focused solely on major morbidity and mortality events. The results demonstrated a 76% reduction in the risk of a composite outcome of all-cause death, lung transplantation, and hospitalization for PAH lasting 24 hours or more, compared to placebo. The FDA has set a target action date of October 25, 2025, under the Prescription Drug User Fee Act. Merck & Co., Inc. (NYSE:MRK) is a leading healthcare company that operates through two main segments including the Pharmaceutical and Animal Health Segments. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
02-07-2025
- Business
- Yahoo
Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer
Merck (NYSE:MRK) might be sitting on a game-changer. The FDA just granted priority review to an application that could expand the label for WINREVAIRits new pulmonary arterial hypertension (PAH) drugbased on results from the Phase 3 ZENITH trial. This wasn't just another study. ZENITH was the first of its kind in PAH to focus purely on hard outcomes like death, transplant, or long-term hospitalization. The kicker? WINREVAIR cut those risks by 76% compared to placebo, so convincingly that the trial was stopped early for efficacy. Merck's updated filing comes with a PDUFA date of October 25, 2025. Warning! GuruFocus has detected 3 Warning Sign with MRK. The setup here is compelling: WINREVAIR is already approved in over 45 countries based on the STELLAR trial, but ZENITH takes it a step further. The trial zeroed in on patients in WHO functional class III or IVthose with high risk and limited options. Improvement with WINREVAIR showed up early and kept getting better over time. If the label update goes through, this could unlock broader treatment potential and strengthen Merck's positioning in a niche but high-stakes market where 5-year mortality still hovers around 43%. That said, it's not without baggage. WINREVAIR comes with bleeding and blood-related risks, especially in patients already on aggressive therapy. But for a life-threatening condition with few real advances, Merck's data may be compelling enough to outweigh those concerns. For investors, this isn't just another pipeline updateit's a potential inflection point. If approved, WINREVAIR could emerge as a category-defining drug in PAH, giving Merck a differentiated edge in a complex and underserved segment. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-07-2025
- Business
- Yahoo
Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer
Merck (NYSE:MRK) might be sitting on a game-changer. The FDA just granted priority review to an application that could expand the label for WINREVAIRits new pulmonary arterial hypertension (PAH) drugbased on results from the Phase 3 ZENITH trial. This wasn't just another study. ZENITH was the first of its kind in PAH to focus purely on hard outcomes like death, transplant, or long-term hospitalization. The kicker? WINREVAIR cut those risks by 76% compared to placebo, so convincingly that the trial was stopped early for efficacy. Merck's updated filing comes with a PDUFA date of October 25, 2025. Warning! GuruFocus has detected 3 Warning Sign with MRK. The setup here is compelling: WINREVAIR is already approved in over 45 countries based on the STELLAR trial, but ZENITH takes it a step further. The trial zeroed in on patients in WHO functional class III or IVthose with high risk and limited options. Improvement with WINREVAIR showed up early and kept getting better over time. If the label update goes through, this could unlock broader treatment potential and strengthen Merck's positioning in a niche but high-stakes market where 5-year mortality still hovers around 43%. That said, it's not without baggage. WINREVAIR comes with bleeding and blood-related risks, especially in patients already on aggressive therapy. But for a life-threatening condition with few real advances, Merck's data may be compelling enough to outweigh those concerns. For investors, this isn't just another pipeline updateit's a potential inflection point. If approved, WINREVAIR could emerge as a category-defining drug in PAH, giving Merck a differentiated edge in a complex and underserved segment. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
